Skip to main content
. 2011 Mar 23;23(1):78–85. doi: 10.1093/annonc/mdr036

Table 2.

Patients’ characteristics according to pAMPK expression

Negative pAMPK (n = 147), n (%) Positive pAMPK (n = 316), n (%) P valuea
Age, median age (range), years 65 (39–87) 66 (32–90) 0.45
Gender 0.47
    Female 70 (47.6) 162 (51.2)
    Male 77 (52.4) 154 (48.8)
Race 0.08
    Caucasian 129 (87.8) 293 (92.7)
    Non-Caucasian 18 (12.2) 23 (7.3)
Histology 0.06
    Adenocarcinoma 104 (70.7) 195 (61.7)
    Squamous cell carcinoma 43 (29.3) 121 (38.3)
Smoking 0.045
    Never smoker 10 (6.8) 39 (12.3)
    Former smoker 62 (42.2) 150 (47.5)
    Current smoker 75 (51.0) 127 (40.2)
(Neo)adjuvant treatment 0.47
    No 65 (44.2) 148 (46.8)
    Neoadjuvant 10 (6.8) 30 (9.5)
    Adjuvant 38 (25.9) 91 (28.8)
    Both 13 (8.8) 18 (5.7)
    Unknown 21 (14.3) 29 (9.2)
T categoryb 0.61
    T1 63 (42.9) 115 (36.4)
    T2 68 (46.3) 162 (51.3)
    T3 6 (4.1) 16 (5.1)
    T4 10 (6.8) 23 (7.3)
N categoryb 0.66
    N0 97 (66.9) 224 (70.1)
    N1 26 (17.9) 52 (16.5)
    N2 22 (15.2) 40 (12.7)
    Nx 2 (1.4) 0 (0.0)
Final stageb 0.45
    I 82 (55.8) 195 (61.7)
    II 50 (34.0) 90 (28.4)
    III and IV 15 (10.2) 31 (9.8)
a

P values are calculated by Wilcoxon rank sum test for age and by chi-square test for all the other variables.

b

According to the American Joint Committee on Cancer Staging Manual sixth edition.

pAMPK, phosphorylated AMP-activated protein kinase; T, tumor; N, node.